159
Views
1
CrossRef citations to date
0
Altmetric
Research Articles

QTc interval diurnal variations in patients treated with psychotropic medications: implications for the evaluation of drug induced QTc changes

, , , , &
Pages 689-692 | Received 09 Sep 2022, Accepted 11 Oct 2022, Published online: 21 Oct 2022

References

  • Bazett, H. C. (1997). An analysis of the time-relations of electrocardiograms. Annals of Noninvasive Electrocardiology, 2(2), 177–194. https://doi.org/10.1111/j.1542-474X.1997.tb00325.x
  • Crnko, S., Du Pre, B. C., Sluijter, J. P. G., & Van Laake, L. W. (2019). Circadian rhythms and the molecular clock in cardiovascular biology and disease. Nature Reviews. Cardiology, 16(7), 437–447. https://doi.org/10.1038/s41569-019-0167-4
  • Dukes, I. D., & Vaughan Williams, E. M. (1984). Effects of selective alpha 1-, alpha 2-, beta 1-and beta 2-adrenoceptor stimulation on potentials and contractions in the rabbit heart. The Journal of Physiology, 355, 523–546. https://doi.org/10.1113/jphysiol.1984.sp015436
  • European Medicines Agency (2005). The clinical evaluation of QT/QTc Interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (CHMP/ICH/2/04). https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-14-clinical-evaluation-qt/qts-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs-step-5_en.pdf (15 October 2022, date last accessed).
  • Farzam, K., & Tivakaran, V. S. (2022). QT prolonging drugs. In StatPearls. Treasure Island (FL): StatPearls Publishing.
  • Girardin, F. R., Gex-Fabry, M., Berney, P., Shah, D., Gaspoz, J. M., & Dayer, P. (2013). Drug-induced long QT in adult psychiatric inpatients: The 5-year cross-sectional ECG Screening Outcome in Psychiatry study. The American Journal of Psychiatry, 170(12), 1468–1476. https://doi.org/10.1176/appi.ajp.2013.12060860
  • Kim, Y., Kim, A., & Chung, J. Y. (2021). Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation. Journal of Affective Disorders, 285, 120–126. https://doi.org/10.1016/j.jad.2021.02.048
  • Malik, M., & Camm, A. J. (2001). Evaluation of drug-induced QT interval prolongation: Implications for drug approval and labelling. Drug Safety, 24(5), 323–351. https://doi.org/10.2165/00002018-200124050-00001
  • Martins, J. B., & Zipes, D. P. (1980). Effects of sympathetic and vagal nerves on recovery properties of the endocardium and epicardium of the canine left ventricle. Circulation Research, 46(1), 100–110. https://doi.org/10.1161/01.res.46.1.100
  • Nachimuthu, S., Assar, M. D., & Schussler, J. M. (2012). Drug-induced QT interval prolongation: Mechanisms and clinical management. Therapeutic Advances in Drug Safety, 3(5), 241–253. https://doi.org/10.1177/2042098612454283
  • Portaluppi, F., & Hermida, R. C. (2007). Circadian rhythms in cardiac arrhythmias and opportunities for their chronotherapy. Advanced Drug Delivery Reviews, 59(9–10), 940–951. https://doi.org/10.1016/j.addr.2006.10.011
  • Ray, W. A., Meredith, S., Thapa, P. B., Meador, K. G., Hall, K., & Murray, K. T. (2001). Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry, 58(12), 1161–1167. https://doi.org/10.1001/archpsyc.58.12.1161
  • Rubart, M., & Zipes, D. P. (2005). Mechanisms of sudden cardiac death. The Journal of Clinical Investigation, 115(9), 2305–2315. https://doi.org/10.1172/JCI26381
  • Sanguinetti, M. C., & Tristani-Firouzi, M. (2006). hERG potassium channels and cardiac arrhythmia. Nature, 440(7083), 463–469. https://doi.org/10.1038/nature04710
  • Straus, S. M., Bleumink, G. S., Dieleman, J. P., van der Lei, J., 't Jong, G. W., Kingma, J. H., Sturkenboom, M. C., & Stricker, B. H. (2004). Antipsychotics and the risk of sudden cardiac death. Archives of Internal Medicine, 164(12), 1293–1297. https://doi.org/10.1001/archinte.164.12.1293
  • van Noord, C., Eijgelsheim, M., & Stricker, B. H. (2010). Drug- and non-drug-associated QT interval prolongation. British Journal of Clinical Pharmacology, 70(1), 16–23. https://doi.org/10.1111/j.1365-2125.2010.03660.x
  • Vandael, E., Vandenberk, B., Vandenberghe, J., Willems, R., & Foulon, V. (2017). Risk factors for QTc-prolongation: Systematic review of the evidence. International Journal of Clinical Pharmacy, 39(1), 16–25. https://doi.org/10.1007/s11096-016-0414-2
  • Weeke, P., Jensen, A., Folke, F., Gislason, G. H., Olesen, J. B., Andersson, C., Fosbøl, E. L., Larsen, J. K., Lippert, F. K., Nielsen, S. L., Gerds, T., Andersen, P. K., Kanters, J. K., Poulsen, H. E., Pehrson, S., Køber, L., & Torp-Pedersen, C. (2012). Antidepressant use and risk of out-of-hospital cardiac arrest: A nationwide case-time-control study. Clinical Pharmacology and Therapeutics, 92(1), 72–79. https://doi.org/10.1038/clpt.2011.368
  • Yeragani, V. K., Pohl, R., Jampala, V. C., Balon, R., Ramesh, C., & Srinivasan, K. (2000). Increased QT variability in patients with panic disorder and depression. Psychiatry Research, 93(3), 225–235. https://doi.org/10.1016/S0165-1781(00)00119-0

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.